NOVO NORDISK A/S
In the published model solve dated 2026-Q2, anchored at $51.25, NOVO NORDISK A/S (NVO) is priced for -3.5% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 24, 2026 from SEC EDGAR filings.
• Obesity care accounts for 27% of revenue against 67% for diabetes care, so almost the entire company rests on one molecule family and whatever succeeds it. • The oral form of Wegovy, the first GLP-1 pill cleared for obesity in the United States, sold DKK 2.3 billion in its first quarter on the market at a launch cash price of $149 a month for the starting dose [Source: Novo Nordisk Q1 2026 results and January 2026 launch pricing]. • Guidance for 2026 is for adjusted sales and operating profit
Is NVO overvalued? See what's priced in →
1,249 institutional managers reported holding NVO in 13F filings for the quarter ended 2026-03-31. Together they hold about 7% of the company; the top 10 hold 3%. 121 opened new positions that quarter. Held by Dodge & Cox, Franklin Resources, Susquehanna International Group, among others. On the short side, 24.5M shares were sold short as of the 2026-06-15 count, about 0.6% of shares outstanding (1.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
NVO has cut its share count 3.3% over the past five years. It pays a dividend, and has paid one every year in our records (7 and counting), raised 2 years straight. Cash returned over the past three years: $18.77B in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 24, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.